Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Xingpi Yiwei Decoction is a Traditional Chinese Medicine (TCM) herbal formulation being investigated for its potential to prevent metachronous early gastric cancer (MEGC) in patients who have undergone endoscopic resection. Developed and studied by researchers at Peking University First Hospital, the decoction is based on traditional principles of 'awakening the spleen' and 'nourishing the stomach' to address gastric mucosal lesions. It is typically administered orally and is often evaluated in clinical trials alongside complementary therapies like bird-pecking acupuncture. The primary therapeutic goal is to improve gastric mucosal health, as evidenced by reductions in OLGA (Operative Link on Gastritis Assessment) and OLGIM (Operative Link on Gastric Intestinal Metaplasia) scores, which are markers for cancer risk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified xingpi yiwei decoction.